Join Growin Stock Community!

Zenas biopharma, inc.ZBIO.US Overview

US StockHealthcare
(No presentation for ZBIO)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ZBIO AI Insights

ZBIO Overall Performance

ZBIO AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ZBIO Recent Performance

-1.53%

Zenas biopharma, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ZBIO PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ZBIO Key Information

ZBIO Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ZBIO Profile

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.

Price of ZBIO

ZBIO FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ZBIO Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.53
PE Ratio (TTM)
2.61
Forward PE
-
PS Ratio (TTM)
94.30
PB Ratio
7.20
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
100.00%
Net Margin
-1265.99%
Revenue Growth (YoY)
-70.00%
Profit Growth (YoY)
118.96%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-4.53
PE Ratio (TTM)
2.61
Forward PE
-
PS Ratio (TTM)
94.30
PB Ratio
7.20
Price-to-FCF
-
Gross Margin
100.00%
Net Margin
-1265.99%
Revenue Growth (YoY)
-70.00%
Profit Growth (YoY)
118.96%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ZBIO's latest earnings report released?

    The most recent financial report for Zenas biopharma, inc. (ZBIO) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ZBIO's short-term business performance and financial health. For the latest updates on ZBIO's earnings releases, visit this page regularly.

  • How much debt does ZBIO have?

    As of the end of the reporting period, Zenas biopharma, inc. (ZBIO) had total debt of 798K, with a debt ratio of 0. Short-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does ZBIO have?

    At the end of the period, Zenas biopharma, inc. (ZBIO) held Total Cash and Cash Equivalents of 115.57M, accounting for 0.36 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ZBIO's EPS continuing to grow?

    According to the past four quarterly reports, Zenas biopharma, inc. (ZBIO)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.22. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ZBIO?

    Zenas biopharma, inc. (ZBIO)'s Free Cash Flow (FCF) for the period is -41.13M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 32.41% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.